Shorter hospital stays for angioplasty patients who receive abciximab

Journal of Invasive Cardiology

Volumn 12, Issue 4, 2000, Pages 179-186

  Lage, Maureen J ^a   Barber, Beth L ^b   Bowman, Lee ^b   Ball, Daniel E ^b   Bala, Mohan ^a  

^a MIAMI UNIVERSITY   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Hospital stay; Multivariate analysis; Resource consumption; Retrospective study; Sample selection model

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ARTICLE; FEMALE; HUMAN; LENGTH OF STAY; MALE; METHODOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; STATISTICS; TRANSLUMINAL CORONARY ANGIOPLASTY; UNITED STATES;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; LENGTH OF STAY; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; MULTIVARIATE ANALYSIS; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 0034166843     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Mak KH, Challapalli R, Eisenberg MJ, et al. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. Am J Cardiol 1997;80:985-988.
2. Lefkovitz J, Ivanhoe RJ, Califf RM, et al. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1996;70:1045-1051.
3. Califf RM, Lincoff AM, Tcheng JE, Topol EJ. An overview of the results of the EPIC trial. Eur Heart J 1995;6(Suppl L):43-49.
4. Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin β3 blockade with percutaneous coronary intervention. JAMA 1997;78:479-484.
5. Adgey AA. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Am Heart J 1998;4:S43-S55.
6. Tcheng JE. Glycoprotein IIb/IIIa receptor inhibitors: Putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol 1996;31:35-40.
7. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with the use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92.
8. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1096.
9. CAPTURE Study. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349:1429-1435.
10. Kereiakes DJ, Lincoff AM, Miller DP, et al. Abciximab therapy and unplanned coronary stent deployment: Favorable effects on stent use, clinical outcomes, and bleeding complications. Circulation 1998;97:857-864.
11. DiSalvo TG, Paul SD, Lloyd-Jones D, et al. Care of acute myocardial infarction by non-invasive and invasive cardiologists: Procedure use, cost and outcome. J Am Coll Cardiol 1996;27:255-261.
12. Philbin EF, Rogers VA, Sheesley KA, et al. The relationship between hospital length of stay and rate of death in heart failures. Heart Lung 1997;26:177-186.
13. Stearns SC. Hospital discharge decisions, health outcomes, and the use of unobserved information on case-mix severity. Health Serv Res 1991;26:27-51.
14. Brophy JM, DesLauriers G, Boucher B, Rouleau JL. The hospital course and short term prognosis of patients presenting to the emergency room with decompensated congestive heart failure. Can J Cardiol 1993;9:219-224.
15. Vinson JM, Rich MW, Sperry JC, et al. Early readmission of elderly patients with congestive heart failure. J Am Geriatric Soc 1990;38:1290-1295.
16. Lee LF. Generalized models with selectivity. Econometrica 1983;51:507-512.
17. Greene WH. Econometric Analysis. Upper Saddle River, New Jersey: Prentice-Hall, 1997.
18. Heckman J. Sample selection as a specification error. Econometrica 1979;47:153-161.
19. Colton T, Freedman LS, Johnson AL, Machin D. Methods for using large databases in health care research: Problems and promises. Proceedings of the Third Biennial Regenstrief Conference. Stat Med 1991;10:505-670.
20. Treglia M, Nesulsan CA, Dunn RL, Hylan TR. SSRI antidepressant selection and concomitant prescribing of anxiolytics and sedative-hypnotics: Evidence from primary care in the United Kingdom. J Med Economics 1998;1:219-233.
21. Every NR, Spertus J, Fihn SD, et al. Length of hospital stay after acute myocardial infarction in the myocardial infarction triage and intervention (MITI) project registry. J Am Coll Cardiol 1996;28:287-293.
22. Matsui K, Goldman L, Johnson PA, et al. Comorbidity as a correlate of length of stay for hospitalized patients with acute chest pain. J Gen Internal Med 1996;11:262-268.
23. Weissman C. Analyzing intensive care unit length of stay data: Problems and possible solutions. Crit Care Med 1997;25:1594-1600.
24. Barnow BS, Cain GG, Goldberger AS. Issues in the analysis of selectivity bias. In: Stromsdorfer EW, Farkas G (eds). Evaluation Studies Review Annual, Volume 5. Beverly Hills, California: Sage Publications, 1980;42-59.
25. Greene WH. LIMDEP: Version 7.0 User's Manual. Plainview, New York: Econometric Software, 1998.
26. Melfi C, Holleman E, Arthur D, Katz B. Selecting a patient characteristic index for the prediction of medical outcomes using administrative claims data. J Clin Epidemiology 1995;48:917-926.
27. Weitzman S, Cooper L, Chambless L, et al. Gender, racial, and geographic differences in the performance of cardiac diagnostic and therapeutic procedures for hospitalized acute myocardial infarction in four states. Am J Cardiol 1997:79:722-726.
28. Ayanian JZ, Epstein AM. Differences in the use of procedures between women and men hospitalized for coronary heart disease. N Engl J Med 1991:325:221-225.
29. Steingart RM, Packer M, Hamm P, et al. Sex differences in the management of coronary artery disease. N Engl J Med 1991:325:226-230.
30. Maynard C, Every NR, Martin RS, Weaver WD. Long-term implications of racial differences in the use of revascularization procedures (the Myocardial Infarction Triage and Intervention Registry). Am Heart J 1997:33:656-662.
31. Peterson ED, Wright SM, Daley J, Thibault GE. Racial variation in cardiac procedure use and survival following myocardial infarction in the Department of Veterans Affairs. JAMA 1994:271:1175-1180.
32. Ayanian JZ, Udvarheyli IS, Gastonis CA, et al. Racial differences in the use of revascularization procedures after coronary angioplasty. JAMA 1993:269:2642-2646.
33. Wenneker MB, Epstein AM. Racial inequalities in the use of procedures for patients with ischemic heart disease in Massachusetts. JAMA 1989:261:253-257.
34. Pilote L, Califf R, Sapp S, et al. Regional variation across the United States in the management of acute myocardial infarction. N Engl J Med 1995:333:565-572.
35. The Cardiology Working Group. Cardiology and the quality of medical practice. JAMA 1991:265:482-485.
36. The EPIC Investigators. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994;330:956.
37. Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin β3 blockade with percutaneous coronary intervention. JAMA 1997;78:479-484.
38. Goklaney AK, Murphy JD, Hillegass WR. Abciximab therapy in percutaneous intervention: Economic issues in the United States. Am Heart J 1998;135:S90-S97.
39. Mark DB, Talley JD, Topol EJ, et al. Economics assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. Circulation 1996;94:629-635.
40. Lincoff AM, Mark DB, Califf RM, et al. Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade during coronary intervention in the EPILOG trial (Abstr). J Am Coll Cardiol 1997;29:240A.
41. Phillips KA, Luft HS, Ritchie JL. The association of hospital volumes of percutaneous transluminal coronary angioplasty with adverse outcomes, length of stay, and charges in California. Med Care 1995;33:502-514.
42. McAleese P, Odling-Smee W. The effect of complications on length of stay. Ann Surg 1994;220:740-744.
43. McClellan M, McNeil BJ, Newhouse JP. Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables. JAMA 1994;272:859-866.
44. Van Hout BA, Simoons ML. Costs and effects of c7E3 in high risk PTCA patients: An indirect analysis for the Netherlands. Eur Heart J 1995;16(Suppl L):81-85.
45. Lincoff AM, Califf RM, Anderson KM, et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. J Am Coll Cardiol 1997;30:149-156.
46. Hillegass WB. The economics of IIb/IIIa therapy. J Invas Cardiol 1996;8(Suppl B):30B-3B.
47. Zavoina R, McElvey W. A statistical model for the analysis of ordinal level dependent variables. J Math Sociology 1975;13:103-120.